fbpx

Our dedicated research arm Sinclair DIRECT (Dermatology Investigational Research Education, and Clinical Trials Centre) was founded in 2010 by our principal dermatologist, Professor Sinclair. It is Australia’s largest dedicated Dermatology research centre and aims to help deliver breakthrough science that has life changing impact.

The Sinclair DIRECT team is supported by over a dozen operational members made up of Principal Investigators, Sub-Investigators, Research Scientists, Clinical Trials Coordinators, Clinical Trials Assistants, Lab Assistants and Research Assistants. DIRECT achieved global number 1 recruiter status on four clinical studies across 132 sites over 22 countries. An achievement we are very proud of.

Research Team

Principal Director

  • Professor Rod Sinclair

Principal Investigators

  • Professor Rod Sinclair
  • Dr Samantha Eisman

Research Fellows

  • Dr Rebekka Jerjen
  • Dr Jared John
  • Dr Lara Carvalho
  • Dr Ameshin Moodley
  • Dr Kevin Koh
  • Dr Dmitri Wall
  • Dr Nekma Meah
  • Dr Katherine York
  • Dr Bevin Bhoyrul

Chief Research Scientist

  • A/prof. Leslie Jones

Senior Research Scientist & Research Manager

  • Ms Laita Bokhari

Research Papers

Professor Sinclair is one of the most highly-cited clinical and research dermatologist in Australia and has personally contributed more than 500 research publications including 7 textbooks to date. Here are some articles our team has published that we would like to share with you.

secure derm

Surveillance Epidemiology of Coronavirus Under Research Exclusion (SECURE) -DERM is a close international collaboration between clinicians, scientists and patients to collect anonymized data concerning patient outcomes as a result of the COVID-19 pandemic.

COVID-19 has created an unprecedented global public health emergency. The pandemic has placed an immense strain on healthcare systems and societal infrastructure worldwide. Most patients exhibit mild-to-moderate symptoms and recover without sequelae, however around 15% develop severe pneumonia and 5% progress to acute respiratory distress syndrome, septic shock and/or multiple organ failure, associated with high mortality. There is an urgent need to better understand the risk factors leading to poorer outcomes.

The SECURE-DERM project offers to link the international clinical, scientific and public health dermatological communities with the common aim of gathering observational data on COVID-19 outcomes in alopecia and atopic dermatitis on a global scale. SECURE-AD and SECURE-Alopecia are web-based registries for clinicians to report COVID-19 outcomes in atopic dermatitis and Alopecia respectively. Both registries have received robust support from major international dermatological professional and patient organisations.

We now encourage clinicians worldwide to participate in this collaboration.

We hope you will actively contribute to this voluntary reporting system. Through broadscale participation and collaboration, we will be able to answer these very pressing questions for our Alopecia and AD patients as well as their caregivers.

This collaboration has been sponsored by National & International Skin Registry Solutions CLG, Dublin Ireland (a registered charity RCN 20205667)

secure alopecia

We encourage clinicians worldwide to report ALL cases of COVID-19 in their alopecia patients treated with systemic immunomodulating medication, regardless of severity (including asymptomatic patients detected through public health screening).

Reporting a case to this (SECURE)-Alopecia registry should take approximately 5 minutes. Please report only confirmed COVID-19 cases, and report after sufficient time has passed to observe the disease course through resolution of acute illness and/or death.

With the collaboration of the international alopecia community, we will rapidly be able to define the impact of COVID-19 on patients with alopecia who are treated with systemic immunomodulating medication and how factors such as age, comorbidities, and systemic immunomodulating treatments impact COVID outcomes.

This is an international effort—we are counting on robust participation and collaboration from clinicians. The alopecia community will be provided with regularly updated summary information about reported cases, including numbers of cases by country, number of cases by treatment, etc. Regular open access summaries of all reported cases in SECURE-Alopecia will be provided for the benefit of the international alopecia community.

secure ad

We encourage clinicians worldwide to report ALL cases of COVID-19 in their AD patients, treated with or without systemic immunomodulating medication, regardless of severity (including asymptomatic patients detected through public health screening).

Reporting a case to SECURE-AD registry should take approximately 5 minutes. Please report all confirmed or clinically suspected COVID-19 cases, and report after sufficient time has passed to observe the disease course through resolution of acute illness and/or death.

With the collaboration of the international AD community, we will rapidly be able to define the impact of COVID-19 on patients with AD who are treated with systemic immunomodulating medication and how factors such as age, comorbidities, and AD systemic immunomodulating treatments impact COVID outcomes.

This is an international effort—we are counting on robust participation and collaboration from clinicians. The AD community will be provided with regularly updated summary information about reported cases, including numbers of cases by country, number of cases by treatment, etc. Similar to SECURE-Alopecia, open access summaries of all reported cases in SECURE-AD will be provided for the benefit of the international AD community.

Accreditations & Memberships

Australasian Hair and Wool Research Society
victoria
international academy cosmetic dermatology
european medecines agency
gpce
deakin university
congress dermatology
bellberry limted
australiasian college dermatologists
australian government national health
australian government ip
australian clinical trials
asdr
albinism fellowship australia
aaaf
ahsf
american dermatological association
british association of dermatology
epworth
international society of dermatology
university of melbourne
Book An Appointment
Shop